Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer.

Brassard, Maryse

Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. [electronic resource] - The Journal of clinical endocrinology and metabolism Sep 2011 - 2741-9 p. digital

Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1945-7197

10.1210/jc.2010-2771 doi


Adenocarcinoma, Follicular--blood
Adenocarcinoma, Papillary--blood
Adult
Aged
Aged, 80 and over
Blood Glucose
Calcium--blood
Cross-Over Studies
Enzyme Inhibitors--therapeutic use
ErbB Receptors--antagonists & inhibitors
Female
Humans
Male
Middle Aged
Parathyroid Hormone--blood
Piperidines--therapeutic use
Proto-Oncogene Proteins c-ret--antagonists & inhibitors
Quinazolines--therapeutic use
Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors
Testosterone--blood
Thyroid Neoplasms--drug therapy
Treatment Outcome
Vitamin D--blood